eXoZymes Inc. (NASDAQ:EXOZ) completed a 100‑fold scale‑up of its N‑trans‑caffeoyltyramine (NCT) production, achieving a feedstock‑to‑product conversion rate of more than 99%. The run was performed under partner‑operated conditions at Cayman Chemical, underscoring the robustness and transferability of the company’s AI‑engineered, cell‑free exozyme platform.
The milestone addresses a long‑standing bottleneck in biomanufacturing: the difficulty of scaling complex enzymatic reactions from gram‑scale laboratory tests to industrial volumes. By demonstrating that the exozyme system can maintain near‑perfect conversion at 100‑fold scale, eXoZymes validates the core premise that its platform can deliver cost‑efficient, scalable production of small‑molecule nutraceuticals. The company remains pre‑revenue and continues to post operational losses, but the scale‑up signals a critical step toward commercial viability and a potential path to profitability as the technology matures.
CEO Michael Heltzen said, “Scaling a complex biocatalytic reaction by 100× while sustaining high feedstock conversion strengthens our belief that exozymes will form the foundation of the next generation of biomanufacturing.” Dr. Tyler Korman, Chief Scientific Officer, added, “Achieving such high conversion rates at scale represents significant validation of our approach and supports the growing evidence that cell‑free enzyme pathways can overcome the limitations of traditional manufacturing.”
The successful scale‑up enhances eXoZymes’ competitive positioning against established enzyme producers and other synthetic biology firms that struggle with scale. It also reinforces the company’s narrative of rapid, cost‑efficient development cycles, which investors view as a key differentiator in a market where time‑to‑market and production cost are decisive factors. The event also provides a tangible data point that can be leveraged in future funding rounds and partnership negotiations.
Looking ahead, eXoZymes is working on downstream isolation and full data analysis, with additional technical details expected in early 2026. The company plans to apply the validated exozyme platform to other nutraceuticals and potentially to pharmaceutical intermediates, expanding its addressable market beyond the current NCT focus. The scale‑up therefore represents both a proof of concept for the technology and a launchpad for broader commercial applications.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.